Identification of Cardiac Liability in Drug Discovery
In 2013 the Cardiac Safety Research Consortium (CSRC), the Health and Environmental Sciences Institute (HESI), and the US Food and Drug Administration (FDA) proposed a paradigm to improve the assessment of the proarrhythmic risk of therapeutic compounds. This paradigm, the Comprehensive in-vitro Proarrhythmia Assay (CiPA), was introduced to provide a more complete assessment of proarrhythmic risk by evaluating and implementing currently available high throughput methods.
Download this app note to discover how patch-clamp can be used as part of an integrated risk assessment in:
- First-in-human studies
- Later stages of clinical development
